Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Prostate cancer
State:  North Carolina
Country:  U.S.A.
Results 1-25 of 32 for your search:
Start Over
A Study to Evaluate the Potential Increased Risk of Seizures Among Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated With Enzalutamide
Phase: Phase IV
Type: Supportive care
Age: Not specified
Trial IDs: 9785-CL-0403, NCI-2014-01193, 2013-003022-92, U1111-1157-0224, NCT01977651
Surgery with or without Docetaxel and Leuprolide Acetate or Goserelin Acetate in Treating Patients with High-Risk Localized Prostate Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CALGB 90203, NCI-2009-00496, CDR0000526353, NCT00430183
Radiation Therapy with or without Androgen-Deprivation Therapy in Treating Patients with Prostate Cancer
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: RTOG 0815, NCI-2011-01948, CDR0000648194, NCT00936390
Diet in Altering Disease Progression in Patients with Prostate Cancer on Active Surveillance
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 50 to 80
Trial IDs: CALGB 70807, NCI-2011-02613, CDR0000687958, NCT01238172
Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients with Prostate Cancer
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: RTOG 0924, NCI-2011-02674, CDR0000701128, PRTOG-0924_A03PAMDREVW01, NCT01368588
Androgen Deprivation Therapy and Orteronel or Bicalutamide in Treating Patients with Newly Diagnosed Metastatic Prostate Cancer
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: S1216, NCI-2012-02876, SWOG-S1216, NCT01809691
Enzalutamide with or without Abiraterone Acetate and Prednisone in Treating Patients with Castration-Resistant Metastatic Prostate Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: A031201, NCI-2013-01737, CALGB-A031201, NCT01949337
Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: MDV3100-14, NCI-2013-02393, NCT02003924
Surgery or Non-surgical Management in Treating Patients with Intra-abdominal Cancer and Bowel Obstruction
Phase: Phase III
Type: Supportive care
Age: 18 and over
Trial IDs: S1316, NCI-2014-01497, SWOG/S1316, NCT02270450
Hypofractionated Radiation Therapy after Prostatectomy in Treating Patients with Prostate Cancer
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 16604, NCI-2013-00618, 16604 PC-HYPOFX, PC-HYPOFX, NCT01868386
A Study to Evaluate Oral VT-464 in Patients With Castration-Resistant Prostate Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: INO-VT-464-CL-001, NCI-2014-00229, VMT-VT-464-CL-001, NCT02012920
A Study to Evaluate Once-Daily Oral VT-464 in Patients With Castration-Resistant Prostate Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: INO-VT-464-CL-004, NCI-2015-00285, NCT02361086
Abiraterone Acetate and Prednisone With or Without Veliparib in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 12-0109, NCI-2012-01149, CDR0000730114, UCCRC-IL057, 9012, IL057, NCT01576172
Abiraterone Acetate, Radiation Therapy, and Hormone Therapy in Treating Patients with Unfavorable-Risk Localized Prostate Cancer
Phase: Phase II
Type: Treatment
Age: 20 to 80
Trial IDs: Pro00044071, NCI-2013-01803, NCT01717053
Abiraterone Acetate Alone, or Abiraterone Acetate and Degarelix, or Degarelix Alone in Treating Patients with Prostate Cancer Previously Treated with Surgery
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 12-187, NCI-2012-03130, c11-092, NCT01751451
Carbohydrate-Restricted Diet in Treating Patients with Previously Treated Prostate Cancer
Phase: Phase II
Type: Treatment
Age: 20 and over
Trial IDs: Pro00041857, NCI-2013-00581, 00041857, NCT01763944
A Phase II Trial of MLN8237 in Patients With Metastatic Castrate Resistant and Neuroendocrine Prostate Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 1210013164, NCI-2014-01689, NCT01799278
CYT107 with or without Vaccine Therapy in Treating Patients with Metastatic Hormone-Resistant Prostate Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CITN12-03, NCI-2013-00998, CITN12-03 IL7, NCT01881867
Abiraterone Acetate and Prednisone in Treating African American and Caucasian Patients with Hormone-Resistant Metastatic Prostate Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: Pro00046383, NCI-2014-00260, 212082PCR2018, DUMC Pro00046383, NCT01940276
Androgen Deprivation Therapy, Enzalutamide, and Radiation Therapy in Treating Patients with Recurrent Prostate Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: Pro00049865, NCI-2014-01161, DUMC Pro00049865, NCT02057939
Abiraterone Acetate with or without Cabazitaxel in Treating Patients with Metastatic Hormone-Resistant Prostate Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 14-046, NCI-2014-01894, c12-108, NCT02218606
Radium Ra 223 Dichloride in Reducing Pain in Patients with Symptomatic Metastatic Hormone-Resistant Prostate Cancer
Phase: Phase II
Type: Supportive care
Age: 18 and over
Trial IDs: 14-098, NCI-2014-02542, c13-124, NCT02278055
Tasquinimod and Cabazitaxel in Treating Patients with Metastatic Hormone Resistant Prostate Cancer
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 79
Trial IDs: Pro00032421, NCI-2013-01900, c11-082, NCT01513733
Stereotactic Body Radiation Therapy in Treating Patients with Metastatic Breast Cancer, Non-small Cell Lung Cancer, or Prostate Cancer
Phase: Phase I
Type: Natural history/Epidemiology, Treatment
Age: 18 and over
Trial IDs: NRG-BR001, NCI-2014-00702, NCT02206334
Start Over